Labopharm Falls 50 Percent On Second FDA Approvable Letter

Cypress Raises $72.9M Publicly Following Phase III Trial Success

Cypress Raises $72.9M Publicly Following Phase III Trial Success

Gilead Reports Positive Phase III Results On CF Drug; Plans NDA

Gilead Reports Positive Phase III Results On CF Drug; Plans NDA

Allon Completes C$15M Funding For Neurodegenerative Programs

Allon Completes C$15M Funding For Neurodegenerative Programs

Avalon Raises $20M Privately To Fund Drug Development

Avalon Raises $20M Privately To Fund Drug Development

Celldex Starts Phase II/III Trial Of Peptide Vaccine In Brain Cancer